SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Financials Shanghai MicroPort Endovascular MedTech Co., Ltd.
Equities
688016
CNE100003MJ5
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.3 CNY | -4.08% |
|
-5.27% | -10.20% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,578 | 18,081 | 17,904 | 13,607 | 16,101 | 15,074 | - | - |
| Enterprise Value (EV) 1 | 10,578 | 17,030 | 16,669 | 12,639 | 13,145 | 12,375 | 12,056 | 11,181 |
| P/E ratio | 63.6 x | 84.3 x | 56.7 x | 38.1 x | 28.6 x | 23.2 x | 18.7 x | 14.1 x |
| Yield | 0.44% | 0.36% | 0.84% | 1.22% | 1.54% | 2.15% | 2.58% | 3.42% |
| Capitalization / Revenue | 31.7 x | 38.4 x | 26.2 x | 15.2 x | 13.6 x | 9.77 x | 7.74 x | 5.93 x |
| EV / Revenue | 31.7 x | 36.2 x | 24.3 x | 14.1 x | 11.1 x | 8.02 x | 6.19 x | 4.4 x |
| EV / EBITDA | 62.3 x | 64.1 x | 43.7 x | 28.2 x | 21.6 x | 15.6 x | 12.6 x | 8.6 x |
| EV / FCF | - | - | - | 318 x | 35.7 x | 28.7 x | 27.5 x | 20.7 x |
| FCF Yield | - | - | - | 0.31% | 2.8% | 3.48% | 3.64% | 4.83% |
| Price to Book | 9.92 x | 14.7 x | 12 x | 7.92 x | 4.19 x | 3.45 x | 3.27 x | 2.79 x |
| Nbr of stocks (in thousands) | 107,247 | 107,247 | 107,247 | 107,247 | 123,262 | 123,262 | - | - |
| Reference price 2 | 98.63 | 168.6 | 166.9 | 126.9 | 130.6 | 122.3 | 122.3 | 122.3 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 333.7 | 470.3 | 684.6 | 896.5 | 1,187 | 1,543 | 1,947 | 2,542 |
| EBITDA 1 | 169.9 | 265.5 | 381.1 | 448.7 | 608.8 | 792.6 | 953.2 | 1,301 |
| EBIT 1 | 164.3 | 249.9 | 362.8 | 415.2 | 573.9 | 759.4 | 950.8 | 1,236 |
| Operating Margin | 49.22% | 53.15% | 52.99% | 46.31% | 48.34% | 49.22% | 48.84% | 48.63% |
| Earnings before Tax (EBT) 1 | 164.3 | 249.6 | 361.7 | 413.9 | 572.3 | 757.6 | 955.3 | 1,244 |
| Net income 1 | 141.8 | 214.6 | 315.9 | 356.9 | 492.4 | 647.8 | 799.2 | 1,067 |
| Net margin | 42.48% | 45.64% | 46.14% | 39.81% | 41.48% | 41.98% | 41.06% | 41.99% |
| EPS 2 | 1.550 | 2.000 | 2.946 | 3.329 | 4.570 | 5.261 | 6.545 | 8.686 |
| Free Cash Flow 1 | - | - | - | 39.78 | 368 | 431 | 439 | 540 |
| FCF margin | - | - | - | 4.44% | 31% | 27.94% | 22.55% | 21.24% |
| FCF Conversion (EBITDA) | - | - | - | 8.87% | 60.45% | 54.38% | 46.05% | 41.52% |
| FCF Conversion (Net income) | - | - | - | 11.15% | 74.74% | 66.54% | 54.93% | 50.59% |
| Dividend per Share 2 | 0.4362 | 0.6040 | 1.409 | 1.544 | 2.013 | 2.624 | 3.159 | 4.188 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 174.5 | 257.9 | 200.9 | 205.4 | 232.3 | 285.6 | 336 | 266.8 | 298.7 | 358.1 | 382.6 | 382.6 | 442.1 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 70.51 | 141.4 | 109.1 | 98.7 | 66.02 | 144.5 | 182.4 | 126 | 120.6 | 217.8 | 175.3 | 175.3 | 202.6 | - | - |
| Operating Margin | 40.41% | 54.84% | 54.29% | 48.04% | 28.43% | 50.61% | 54.29% | 47.21% | 40.38% | 60.81% | 45.81% | 45.81% | 45.81% | - | - |
| Earnings before Tax (EBT) 1 | 70.37 | 141.2 | 109.1 | 98.27 | 65.3 | 144.9 | 181.3 | 126 | 120.5 | 216.8 | 178.7 | 178.7 | 241.2 | - | - |
| Net income 1 | 65.87 | 123.5 | 91.55 | 85.85 | 56 | 124.8 | 155.1 | 108.9 | 104 | 184.3 | 152.8 | 154 | 209.1 | - | - |
| Net margin | 37.75% | 47.88% | 45.57% | 41.79% | 24.11% | 43.71% | 46.15% | 40.81% | 34.81% | 51.47% | 39.95% | 40.25% | 47.3% | - | - |
| EPS 2 | 0.6174 | 1.154 | 0.8524 | 0.7987 | 0.5235 | 1.161 | 1.450 | 1.020 | 0.9463 | 1.497 | 1.240 | 1.249 | 1.697 | - | - |
| Dividend per Share 2 | 1.409 | - | - | - | 1.544 | - | - | - | 2.013 | - | - | - | 2.642 | - | - |
| Announcement Date | 2/24/22 | 4/29/22 | 8/25/22 | 10/28/22 | 2/27/23 | 4/27/23 | 7/28/23 | 10/27/23 | 2/23/24 | 4/26/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,051 | 1,234 | 968 | 2,956 | 2,699 | 3,017 | 3,893 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | 39.8 | 368 | 431 | 439 | 540 |
| ROE (net income / shareholders' equity) | 24.7% | 18.7% | 23.2% | 22.2% | 26.4% | 15.1% | 17.9% | 19.2% |
| ROA (Net income/ Total Assets) | 19.9% | 17% | 20.2% | - | 15.8% | 14% | 15.7% | 17.5% |
| Assets 1 | 712.3 | 1,266 | 1,566 | - | 3,119 | 4,643 | 5,079 | 6,117 |
| Book Value Per Share 2 | 9.940 | 11.50 | 13.90 | 16.00 | 31.20 | 35.50 | 37.50 | 43.90 |
| Cash Flow per Share 2 | 1.570 | 2.030 | 2.800 | 3.110 | 4.530 | 5.080 | 6.330 | 7.930 |
| Capex 1 | 21.2 | 26.2 | 89.6 | 294 | 190 | 354 | 215 | 213 |
| Capex / Sales | 6.36% | 5.58% | 13.08% | 32.79% | 16.03% | 22.95% | 11.05% | 8.39% |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
122.3
CNY
Average target price
157
CNY
Spread / Average Target
+28.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.38% | 2.08B | |
| +10.11% | 126B | |
| -5.76% | 11.33B | |
| +6.07% | 9.27B | |
| +37.46% | 5.5B | |
| +8.53% | 3.45B | |
| -8.69% | 2.81B | |
| -10.91% | 2.09B | |
| -23.21% | 1.78B | |
| -10.60% | 1.14B |
- Stock Market
- Equities
- 688016 Stock
- Financials Shanghai MicroPort Endovascular MedTech Co., Ltd.
